Alexion Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript Seeking Alpha We're currently focused on clinical programs in four such disorders, acute humoral transplant rejection STEC-HUS, neuromyelitis optica and myasthenia gravis. And we will drive these programs forward throughout 2012. |
